Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI -1.26%74 3-Year ROIIC % is 484.58 as of Dec. 2025. GuruFocus rates SMTI with a GF Score™ of 74/100 and a GF Value™ of $45.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Sanara MedTech ranks better than 96.61% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sanara MedTech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 484.58%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sanara MedTech's 3-Year ROIIC % or its related term are showing as below:
SMTI's 3-Year ROIIC % is ranked better than 96.61% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs SMTI: 484.58
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sanara MedTech 3-Year ROIIC % Related Terms
Sanara MedTech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs EMBC, KRMD, UTMD: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's 3-Year ROIIC % falls into.
Sanara MedTech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 9.146 (Dec. 2025) - -7.1018992 (Dec. 2022) )
/
( 53.006 (Dec. 2025) - 49.653 (Dec. 2022) )
=
16.2478992
/
3.353
=
484.58%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sanara MedTech (SMTI) has a 3-Year ROIIC % of 484.58 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #27 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 3.4%.
Is Sanara MedTech's 3-Year ROIIC % too high?
Sanara MedTech's current 3-Year ROIIC % is 484.58. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Sanara MedTech's value of 484.58 is 29812.3% above this industry median. Based on the distribution chart, Sanara MedTech ranks #27 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sanara MedTech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's 3-Year ROIIC % compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #27 out of 796 companies for 3-Year ROIIC %. This places Sanara MedTech in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.62. Sanara MedTech's value of 484.58 is 29812.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current 3-Year ROIIC % of 484.58 is 29812.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current 3-Year ROIIC % is 484.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.78, compared to a current price of $25.00 — trading 45.4% below its estimated fair value. The current 3-Year ROIIC % is 484.58 and 29812.3% above the Medical Devices & Instruments industry median of 1.62. Sanara MedTech's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current 3-Year ROIIC % is 484.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $25.00 is trading 45.4% below its estimated GF Value™ of $45.78.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
3-Year ROIIC %: 484.58
GF Value™: $45.78 vs. price of $25.00 (45.4% below fair value)
Industry Position: 29812.3% above the Medical Devices & Instruments median (#27 of 796)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
74GF Score
Get the complete analysis for SMTI
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
